Indiana company quits Missouri Medicaid contract
Indianapolis-based SynCare has ended its contract to screen Missouri Medicaid recipients after numerous complaints about its job performance.
Indianapolis-based SynCare has ended its contract to screen Missouri Medicaid recipients after numerous complaints about its job performance.
Officials with the Missouri Department of Health and Senior Services say they had to hire 13 temporary workers and shift as many as 20 state workers from their regular jobs after withering consumer complaints against SynCare LLC of Indiana.
Indianapolis-based SynCare LLC, hired to determine the eligibility of Missouri Medicaid patients for in-home care, has "been a complete disaster from the beginning," statewide health care advocates charge.
Why not look at the entire neighborhood instead of just this old site?
Angela Smith, an attorney for hospitals and physicians at Indianapolis-based Hall Render Killian Heath & Lyman P.C., spoke about Medicare’s value-based purchasing program, a federal initiative that will attempt to shift health care payments from the fee-for-service model to one based on health outcomes. On July 1, hospitals began being scored on their performance in 13 categories, including processes, patient outcomes and patient satisfaction surveys. How hospitals score could boost or diminish all their Medicare payments by as much as 1 percent, beginning in October 2012.
New drug for metastatic melanoma packaged with genetic test should help Roche sell more of its cobas 4800 laboratory testing systems.
Indianapolis doctor tell researchers that hospitals are paying more than $1 million a year to employ some cardiologists.
Eli Lilly and Co. spent $1.9 million lobbying the federal government in the first quarter, focusing on the health care overhaul and overseas pricing reform, among many other issues.
WellPoint lobbied on issues tied to the overhaul's implementation and regulations for accountable care organizations, which are networks of hospitals, doctors, rehabilitation centers and other providers that coordinate a patient's care.
Two years into the economic recovery, bright spots in the Indiana job market are still hard to find. The insurance industry is one of the few glimmers of light on Indiana’s horizon. Others include engine makers, nursing homes and temp agencies.
Arcadia Resources Inc.’s share price dwindled to just 5 cents as of late Tuesday morning, following the company's announcement that it was delisting its stock and had suffered another quarterly loss.
Hartford-based Aetna Inc. and Philadelphia-based Cigna Corp., the nation’s third- and fifth-largest health insurers respectively, have announced their departure from Indiana’s individual health insurance market.
The Warsaw-based company has sued seven law firms this year and sent warning letters to at least three more, saying their ads and Internet postings distorted the safety record of its $1.8 billion-a-year knee business.
Warsaw-based DePuy Orthopaedics expects to spend $20 million on manufacturing equipment and $7 million on research and development equipment and have it installed before 2014.
Rochester Medical Implants plans to move operations from Rochester to Noblesville in October. The company has 28 employees.
The West Lafayette-based biotech firm raised about $66.8 million by selling nearly 6.7 million shares of company stock, priced at $12.26 per share.
Indiana asked a federal appeals court Monday to lift a judge's order blocking parts of a new abortion law that cuts some public Planned Parenthood funding, saying the issue should be decided by Medicaid officials and not the courts.
Deloitte found that 20 percent of consumers have cut back on health care spending and 75 percent say the economic slowdown has had some impact on their willingness to spend on health care.
With recession-weary Americans going to the doctor less, health insurer WellPoint Inc. should be enjoying higher profits. But it isn’t working out that way.
The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., overturned Friday a judge’s decision that Lilly’s patent on attention-deficit treatment Strattera was invalid.